UNSPSC 51295101: Beloxepin

This classification denotes an antidepressant agent with the molecular formula C19H21NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier G905IN29U4, chemically known as ( -)-cis-1,3,4,13b-tetrahydro-2,10-dimethyldibenz(2,3:6,7)oxepino(4,5-c)pyridin-4a(2h)-ol but generally known as beloxepin, which bears US NIH Compound Identifier 166560. European Medicines Agency schedules Beloxepin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05689MIG.

UNSPSC 51295101 Beloxepin, a Commodity code, identifies pharmaceutical products that state and local governments procure for community health and emergency response programs. The recent solicitation activity under this code reflects actual purchasing of naloxone and related drug-intervention systems rather than beloxepin itself, indicating a mismatch between the code's nominal scope and current procurement practice. State and local issuing bodies—primarily county health departments and public health authorities—use this code to source pharmaceutical supplies and medical countermeasures for opioid overdose response and substance abuse intervention initiatives. The work involves sourcing finished pharmaceutical products with established supply chains, quarterly or regular delivery schedules, and compliance with standard commercial contracting terms including insurance, drug-free workplace certification, and E-Verify requirements.

Seminole County, Florida, posted an IFB on June 30, 2026 (with response deadline July 26, 2023 as stated in the notice, though the posting date is current-year) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to the Seminole County Community Health Building in Sanford. The procurement is potentially FEMA-funded and requires vendors to submit unit costs electronically, include all shipping and delivery costs in proposals, and comply with federal environmental and acquisition regulations. The contract structure includes an initial two-year term with a one-year renewal option and a three-month probationary period. The opportunity shows limited recent activity under this code; sourcing appears concentrated in Florida county health systems, and the actual pharmaceutical products being purchased diverge significantly from the code's stated commodity name, suggesting either code misapplication or a data-quality issue in the state and local taxonomy system.